Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 August 2021 | Story André Damons | Photo Charl Devenish
Itumeleng Mabusa, analyst in the South African Doping Control Laboratory (SADoCoL) hosted by the University of the Free State (UFS), says women in South Africa and the world at large are still facing the most discrimination in the workplace.

It is time that women realise their brilliant leadership qualities. Women are more sensitive and intuitive and bring a different dimension of leadership to the workplace.

For Itumeleng Mabusa, analyst at the South African Doping Control Laboratory (SADoCoL) hosted by the University of the Free State (UFS), this is one of the ways to address the challenges that women still face. Mabusa believes the opportunities for women are not as prominent as it should be and believe that gender discrimination in the workplace still exists and should be addressed.

Mabusa, who has been a member of SADoCoL since April 2015, analyses urine samples from athletes to test for prohibited drugs in sports. Her day-to-day work involves sample extractions, running the extracts on analytical instruments such as the high-performance liquid chromatography (HPLC) or gas chromatography (GC) machines, and analysing the data to see if there are any performance-enhancing drugs that are prohibited by the World Anti-Doping Agency (WADA).

Women still face the most discrimination in the workplace

According to her, women in South Africa and the world at large are still facing the most discrimination in the workplace. Women still have to fight to get their views across, and they are still not taken seriously because of patriarchal stereotypes. 

“In some corporate settings, women are still remunerated as well as men, regardless of both being in the same position and equally talented. It is hard enough to be equally recognised as a professional in your own field of expertise as a woman, which is exacerbated if you are a woman of colour. The other most pressing issue is the high prevalence of gender-based violence, with women holding the record for high incidents of violence against them,” says Mabusa.

Addressing the challenges

These challenges, says Mabusa, can be addressed by allowing women to do any job that a man can do. Women in leadership are often disregarded and their judgments are always questioned, she says. 

“There has to be more outreach programmes to teach young girls at a very young age that they can be leaders in absolutely any career they desire, from science, engineering, and aviation – to name but a few. Most importantly, leaders should groom the women in their organisations to one day take over the higher positions, and not always leave them for men.” 

“My opinion regarding issues of gender-based violence is that it must be addressed from an early age, in addition to teaching and preparing the girl-child to fend off danger. I think the boy child should also be empowered and taught to be self-sufficient, and not be egotistical, but respectful towards women of any age. Boys and girls should be groomed to be able to co-exist cohesively in a society where they both have equal chances of achieving greatness.”  
What is the most interesting thing to you in the field of anti-doping science?

As a WADA-certified scientist, Mabusa says the best and the worst part of her field is when she has to take part in external quality assessment scheme (EQAS). All the WADA-accredited laboratories in the world must take part in the analyses of the same samples three times a year at the same time. 

“These are both nerve-wracking and exciting all at the same time; it always reminds me of the feeling I used to get when I had to write final exams. I like comparing my statistical results with the rest of the world, for example finding out what quantitative concentration values and Z-scores the rest of the world obtained for their analysis compared to mine.” 

“It is also very interesting to find the scientific evidence and analysis you completed, led to the prosecution of an athlete due to an anti-doping rule violation. I also love doing scientific research and being able to share it with the rest of the world. Working with different analytical equipment and different software – from GC-MS and LC-MS to LC-UV – is exciting,” says Mabusa.  

Community value impacts life as a scientist and woman

Mabusa says as a woman, especially a black woman being given the chance to use her scientific skills as a WADA-certified scientist, it is an honour, as it gives everyone competing in sports in Africa a fair chance to compete. By testing these athletes, she explains, she is making sure that everyone plays fairly without their performances being influenced by any prohibited drugs. 

“Among the prohibited drugs are also drugs of abuse, including for example, cocaine and MDMA (ecstasy). By testing athletes for these drugs, I am helping the athletic community to try to stay off illegal recreational drugs.” 

Playing her part in the Olympics and coping with challenges

With the Olympic Games taking place between July and August, Mabusa says it is a great feeling to know that she is part of a team of scientists who are producing test reports that will ultimately determine whether tested athletes will be eligible or banned from representing their African countries at the Games.

According to her, they have a high volume of samples to analyse on a daily basis, because of all the sports competitions in South Africa and the continent in preparation for the Tokyo Olympics. 

Mabusa says the challenges associated with this work include the extremely strict rules of analysis, called the International Standard of Laboratories (ISL), set for all accredited laboratories to follow. The strict timelines that they all have to stick to in order to report the results to clients on time – no matter how many samples there are – is also a challenge. 

“This means analysing a large amount of data as accurately as possible in the shortest time I can. A skill I had to harness and embrace and learned to perfect over time, is the ability to pay very close attention to detail; this comes in handy when dealing with analytical work.” 

“There is also countless paperwork to fill in in order to follow a chain of custody for a sample. Each and every step gets recorded, from sample reception all the way to reporting; paying attention to detail comes in quite handy through all this,” says Mabusa.  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept